MyFinsight
Home
Blog
About
Contact
Download
Download image
Sales and maturities
of marketable...
$133,366K
Proceeds from issuance of
stock from employee...
$327K
Net cash provided by
investing activities
$72,119K
Net cash provided by
financing activities
$327K
Canceled cashflow
$61,247K
Net increase
(decrease) in cash and cash...
$6,858K
Canceled cashflow
$65,588K
Purchases of marketable
securities
$59,608K
Acquisition of property and
equipment
$1,639K
Stock-based compensation
expense
$8,523K
Prepaid and other
current assets
-$6,283K
Accounts and other
receivables
-$1,785K
Depreciation and
amortization
$854K
Loss on sale or
disposal of assets
-$3K
Net cash used in
operating activities
-$65,588K
Canceled cashflow
$17,448K
Net loss
-$78,685K
Other assets
$2,076K
Other liabilities
-$1,358K
Amortization and premium of
marketable securities, net
$630K
Accounts payable and
accrued expenses
-$287K
Back
Back
Cash Flow
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)
source: myfinsight.com